Literature DB >> 20332655

Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics.

Tanja Guthoff1, Bettina Tietze, Berit Meinhardt, Jan Becher, Rainer Guthoff.   

Abstract

AIMS: The use of the chemotherapeutic cytosine arabinoside (Ara-C) causes an ocular toxic reaction, characterized by aspecific keratopathy. We examined the pathway of the damaged cells by in vivo confocal microscopy.
METHODS: Prospective study of 11 patients with acute myeloic leukemia treated with high-dose Ara-C. Ten eyes developed fluorescein-negative punctate keratopathy, and were examined by slit lamp and in vivo confocal biomicroscopy at days 1, 3-4 and 9-14 after the beginning of ocular symptoms.
RESULTS: In vivo confocal microscopy revealed disseminated highly reflective granular irregular intraepithelial elements in the central cornea, which affected about 3% of epithelial cells. At day 1 of symptoms, these elements were present only in the basal epithelial layer (median 275.5/mm(2)), at days 3-4 they were mainly found in the basal (187.5/mm(2)) but also in the apical layers (96/mm(2)), at days 9-14 they mainly presented in more superficial layers (115/mm(2) apically vs. 15.5/mm(2) in the basal layers). DISCUSSION: The intraepithelial distribution of cells with a granular cytosolic signal evolved over time, reflecting the migration of the necrotic basal cells to the wing cell layer and finally to apical epithelial layers. The desquamation of the necrotic cells is related to the resolution of symptoms, according to the period of the epithelial cell turnover. By confocal microscopy, we could follow the intraepithelial route of cells damaged by Ara-C in vivo. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332655     DOI: 10.1159/000298751

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  7 in total

Review 1.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

2.  Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.

Authors:  Rakesh Popat; Dana Warcel; Jenny O'Nions; Anna Cowley; Sasha Smith; William R Tucker; Kwee Yong; Simona Degli Esposti
Journal:  Haematologica       Date:  2020-02-27       Impact factor: 9.941

Review 3.  Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.

Authors:  Joshua Seth Eaton; Paul E Miller; Mark J Mannis; Christopher J Murphy
Journal:  J Ocul Pharmacol Ther       Date:  2015-11-05       Impact factor: 2.671

4.  N-acetylcysteine supplementation reduces oxidative stress for cytosine arabinoside in rat model.

Authors:  Yasemin Isik Balci; Semra Acer; Ramazan Yagci; Vural Kucukatay; Hakan Sarbay; Kerem Bozkurt; Aziz Polat
Journal:  Int Ophthalmol       Date:  2016-05-23       Impact factor: 2.031

5.  Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients

Authors:  Gökçen Özcan; Ömür Özlenen Uçakhan
Journal:  Turk J Ophthalmol       Date:  2021-04-29

6.  Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.

Authors:  Asim V Farooq; Simona Degli Esposti; Rakesh Popat; Praneetha Thulasi; Sagar Lonial; Ajay K Nooka; Andrzej Jakubowiak; Douglas Sborov; Brian E Zaugg; Ashraf Z Badros; Bennie H Jeng; Natalie S Callander; Joanna Opalinska; January Baron; Trisha Piontek; Julie Byrne; Ira Gupta; Kathryn Colby
Journal:  Ophthalmol Ther       Date:  2020-07-25

Review 7.  Drug-induced corneal deposits: an up-to-date review.

Authors:  Jean-Yves Sahyoun; Saama Sabeti; Marie-Claude Robert
Journal:  BMJ Open Ophthalmol       Date:  2022-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.